Gene-Editing Companies To Watch At J.P. Morgan

Milestones Expected In 2022 For CRISPR and Emerging Technologies

 
• By Andrew McConaghie

Share prices for many gene-editing companies declined in 2021, but the field is burgeoning with novel approaches due to be highlighted at the J.P. Morgan meeting, and one player, Intellia, could move closer to a breakthrough in 2022.

Editas
Editas's first in vivo gene therapy results underwhelmed last year, but the company could build on its leading position in 2022. • Source: Alamy

More from Gene Therapies

More from Advanced Therapies